(S)-N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparationsThe invention includes a granular composition comprising the active ingredient (S)-N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide, wherein a total amount of active ingredient comprises by weight % about 60-90% (S)-N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-y1)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide Form 1 HCl, about 10-30% (S)-N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide amorphous HCl, and about 0-5% (S)-N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide amorphous free base.Medicinal tablet, it includes active ingredient (s)-n- (3- (6- isopropoxypyrid -3- bases) -1h- indazole -5- bases) -1- (2- (4- (4- (1- methyl isophthalic acid h-1,2,4- triazole -3- bases) phenyl) -3,6- dihydropyridines -1 (2h)-yl) -2- oxoethyls) - 3- (methyl mercapto) pyrrolidines -3- formamides, the wherein total amount of active ingredient % by weight count (s)-n- (3- for including about 60-90% (6- isopropoxypyrid -3- bases) -1h- indazole -5- bases) -1- (2- (4- (4- (1- methyl isophthalic acid h-1,2,4- triazole -3- bases) benzene base) -3,6- dihydropyridines -1 (2h)-yl) -2- oxoethyls) 1 hcl of -3- (methyl mercapto) pyrrolidines -3- formamides form, about 10-30% (s)-n- (3- (6- isopropoxypyrid -3- bases) -1h- indazole -5- bases) -1- (2- (4- (4- (1- methyl isophthalic acid h-1, 2,4- triazole -3- bases) phenyl) -3,6- dihydropyridines -1 (2h)-yl) -2- oxoethyls) -3- (methyl mercapto) pyrrolidines -3- first the amorphous hcl of acid amides, and about 0-5% (s)-n- (3- (6- isopropoxypyrid -3- bases) -1h- indazole -5- bases) -1- (2- (4- (4- (1- methyl isophthalic acid h-1,2,4- triazole -3- bases) phenyl) -3,6- dihydropyridines -1 (2h)-yl) -2- oxoethyls) -3- (first sulfenyl) the amorphous free alkali of pyrrolidines -3- formamides.
제약 제제용 (S)-N-(3-(6-이소프로폭시피리딘-3-일)-1H-인다졸-5-일)-1-(2-(4-(4-(1-메틸-1H-1,2,4-트리아졸-3-일)페닐)-3,6-디히드로피리딘-1(2H)-일)-2-옥소에틸)-3-(메틸티오)피롤리딘-3-카르복사미드 조성물본 발명은 유효 성분 (S)-N-(3-(6-이소프로폭시피리딘-3-일)-1H-인다졸-5-일)-1-(2-(4-(4-(1-메틸-1H-1,2,4-트리아졸-3-일)페닐)-3,6-디히드로피리딘-1(2H)-일)-2-옥소에틸)-3-(메틸티오)피롤리딘-3-카르복사미드를 포함하고, 여기서 유효 성분의 총량은 약 60-90 중량%의 (S)-N-(3-(6-이소프로폭시피리딘-3-일)-1H-인다졸-5-일)-1-(2-(4-(4-(1-메틸-1H-1,2,4-트리아졸-3-일)페닐)-3,6-디히드로피리딘-1(2H)-일)-2-옥소에틸)-3-(메틸티오)피롤리딘-3-카르복사미드 형태 1 HCl, 약 10-30 중량%의 (S)-N-(3-(6-이소프로폭시피리딘-3-일)-1H-인다졸-5-일)-1-(2-(4-(4-(1-메틸-1H-1,2,4-트리아졸-3-일)페닐)-3,6-디히드로피리딘-1(2H)-일)-2-옥소에틸)-3-(메틸티오)피롤리딘-3-카르복사미드 비결정질 HCl, 및 약 0-5 중량%의 (S)-N-(3-(6-이소프로폭시피리딘-3-일)-1H-인다졸-5-일)-1-(2-(4-(4-(1-메틸-1H-1,2,4-트리아졸-3-일)페닐)-3,6-디히드로피리딘-1(2H)-일)-2-옥소에틸)-3-(메틸티오)피롤리딘-3-카르복사미드 비결정질 유리 염기를 포함하는 것인 과립 조성물을 포함한다.유효 성분 (S)-N-(3-(6-이소프로폭시피리딘-3-일)-1H-인다졸-5-일)-1-(2-(4-(4-(1-메틸-1H-1,2,4-트리아졸-3-일)페닐)-3,6-디히드로피리딘-1(2H)-일)-2-옥소에틸)-3-(메틸티오)피롤리딘-3-카르복사미드를 포함하고, 여기서 유효 성분의 총량은 약 60-90 중량%의 (S)-N-(3-(6-이소프로폭시피리딘-3-일)-1H-인다졸-5-일)-1-(2-(4-(4-(1-메틸-1H-1,2,4-트리아졸-3-일)페닐)-3,6-디히드로피리딘-1(2H)-일)-2-옥소에틸)-3-(메틸티오)피롤리딘-3-카르복사미드 형태 1 HCl, 약 10-30 중량%의 (S)-N-(3-(6-이소프로폭시피리딘-3-일)-1H-인다졸-5-일)-1-(2-(4-(4-(1-메틸-1H-1,2,4-트리아졸-3-일)페닐)-3,6-디히드로피리딘-1(2H)-일)-2-옥소에틸)-3-(메틸티오)피롤리딘-3-카르복사미드 비결정질 HCl, 및 약 0-5 중량%의 (S)-N-(3-(6-이소프로폭시피리딘-3-일)-1H-인다졸-5-일)-1-(2-(4-(4-(1-메틸-1H-1,2,4-트리아졸-3-일)페닐)-3,6-디히드로피리딘-1(2H)-일)-2-옥소에틸)-3-(메틸티오)피롤리딘-3-카르복사미드 비결정질 유리 염기를 포함하는 것인 제약 정제.